Yungjin Pharm Co Ltd (003520) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Yungjin Pharm Co Ltd KRW 329, price KRW 1,022, upside -67.9%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Yungjin Pharm Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,019 KRW – 6,520 KRW · fair‑value band 245.16 KRW – 328.52 KRW · the 1,022 KRW price screens above the 328.52 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Yungjin Pharm Co in your weekly email
Every Wednesday you see whether Yungjin Pharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products.
Show more
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Stock analysis
Yungjin Pharm Co Ltd (003520) currently trades at 1,022 KRW, while our model-based Fair Value estimate is 328.52 KRW, implying the stock looks roughly 211.1% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 337.11 KRW per share, and 0 of the 6 models we run sit above the 1,022 KRW price.
Bear case: the Earnings-Based group reads lowest at 59.62 KRW, and 6 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: 245.16 KRW (bear) to 328.52 KRW (bull), the price of 1,022 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Yungjin Pharm Co Ltd reported revenue of 254B KRW in FY2025 versus 196B KRW in FY2021, a compound +6.7%/yr. Reported net income was −228M KRW in FY2025.
Key figures
Market cap 218B KRW (≈ $160M) · P/S ratio 1.21 · Net margin −0.1% · Return on equity −5.0% · Return on assets (EBIT) −0.8% · Operating margin −6.7% · Revenue (TTM) 179B KRW · Revenue growth (YoY) −16.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −68%, 003520 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (59.62 KRW to 930.51 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 245.16 KRWFair Value 328.52 KRWBull 328.52 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.2% (2020) → 1.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−68% · Bottom 25%
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)−3% · Below median
Operating margin (TTM)−7% · Bottom 25%
Growth and dividend
Revenue growth−16% · Bottom 25%
Balance sheet
Debt / equity0.53× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
EV/EBITDA25.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)73· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yungjin Pharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/003520
Frequently asked questions
Is Yungjin Pharm Co Ltd (003520) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 328.52 KRW versus a price of 1,022 KRW, about −68% upside (overvalued).
What is the fair value of 003520?
Our model-based fair value for Yungjin Pharm Co Ltd is 328.52 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,022 KRW.
What is the quality score of 003520?
Yungjin Pharm Co Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yungjin Pharm Co Ltd (003520)?
Our model-based price target is the fair value of 328.52 KRW (as of Sep 24, 2026) from 6 valuation models. Cautious scenario 245.16 KRW, optimistic scenario 328.52 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Yungjin Pharm Co Ltd stock forecast for 2026?
Our models put fair value at 328.52 KRW, about −68% upside versus a price of 1,022 KRW (overvalued). Cautious scenario 245.16 KRW, optimistic scenario 328.52 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Yungjin Pharm Co Ltd (003520)?
Yungjin Pharm Co Ltd reported trailing-twelve-month revenue of about 179B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Yungjin Pharm Co Ltd (003520)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yungjin Pharm Co Ltd it is 328.52 KRW per share (as of Sep 24, 2026), against a price of 1,022 KRW. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Yungjin Pharm Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 003520 trades above its calculated fair value: price 1,022 KRW, fair value 328.52 KRW, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003520?
No. The price is what the market pays today (1,022 KRW); the fair value is what the company's own numbers justify (328.52 KRW). For Yungjin Pharm Co Ltd the two are 693.48 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Yungjin Pharm Co Ltd worth?
The market values Yungjin Pharm Co Ltd at about 218B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,022 KRW; our models calculate a fair value of 328.52 KRW per share.
What do the bullish and bearish scenarios say about 003520?
Our models span a range for Yungjin Pharm Co Ltd: cautious scenario 245.16 KRW, base 328.52 KRW, optimistic 328.52 KRW per share (as of Sep 24, 2026, price 1,022 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Yungjin Pharm Co Ltd (003520)?
Balance-sheet figures for Yungjin Pharm Co Ltd (as of Sep 24, 2026): return on equity −5.0%, debt of 0.53 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 003520 from its 52-week high?
Yungjin Pharm Co Ltd trades at 1,022 KRW, about 53% below its 52-week high of 2,170 KRW and at the low of 1,019 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 328.52 KRW is for.
Which stocks are comparable to Yungjin Pharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yungjin Pharm Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 1,022 KRW, calculated fair value 328.52 KRW (−68%), Quality Score 40/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003520 calculated?
We run Yungjin Pharm Co Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 328.52 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Yungjin Pharm Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yungjin Pharm Co Ltd (003520)?
The closing price on Sep 23, 2026 was 1,022 KRW. Our model-based fair value is 328.52 KRW, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yungjin Pharm Co Ltd right now?
The price sits above even our optimistic bull case (328.52 KRW). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Yungjin Pharm Co Ltd
How large is the market capitalisation of Yungjin Pharm Co Ltd (003520)?
The market capitalisation of Yungjin Pharm Co Ltd is 218B KRW (≈ $160M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yungjin Pharm Co Ltd (003520)?
The price-to-sales ratio of Yungjin Pharm Co Ltd is 1.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Yungjin Pharm Co Ltd (003520)?
The net margin of Yungjin Pharm Co Ltd is −0.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yungjin Pharm Co Ltd (003520)?
The return on equity (ROE) of Yungjin Pharm Co Ltd is −5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yungjin Pharm Co Ltd (003520)?
On an EBIT basis the return on assets of Yungjin Pharm Co Ltd is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yungjin Pharm Co Ltd (003520)?
The operating margin of Yungjin Pharm Co Ltd is −6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yungjin Pharm Co Ltd (003520)?
Revenue at Yungjin Pharm Co Ltd is growing −16.0% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yungjin Pharm Co Ltd (003520)?
Earnings per share at Yungjin Pharm Co Ltd are growing −35.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yungjin Pharm Co Ltd (003520) generate?
The free cash flow of Yungjin Pharm Co Ltd is −234M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Yungjin Pharm Co Ltd (003520) carry?
The net debt of Yungjin Pharm Co Ltd is 64.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Yungjin Pharm Co Ltd in the live analysis
One click puts Yungjin Pharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
